Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 7/20 | 0.50 |
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9159765 | 0.84 | HTR2C (0.40) | DRD3DRD2CYP19A1DRD1DRD4 | |
| SCHEMBL10883561 | 0.81 | DRD3 (0.54) | DRD3DRD2CYP19A1CHRNB4CHRNA3 | |
| SCHEMBL9159596 | 0.80 | DRD3 (0.32) | DRD3DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL9157877 | 0.80 | DRD3 (0.32) | DRD3DRD2 | |
| SCHEMBL9301537 | 0.79 | DRD3 (0.35) | DRD3 | |
| SCHEMBL18706863 | 0.73 | DRD3 (0.59) | DRD3DRD2CYP19A1KDM4EALDH1A1 | |
| SCHEMBL9300450 | 0.73 | TLR9 (0.32) | — | |
| SCHEMBL14721136 | 0.73 | SLC6A4 (0.37) | — | |
| SCHEMBL9419138 | 0.72 | CHRNB4 (0.44) | DRD2CHRNB4CHRNA3HTR2AHTR2C | |
| SCHEMBL10062055 | 0.70 | DRD3 (0.59) | DRD3DRD2CYP19A1ALDH1A1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998415-B2 | Pyrazolyl derivatives; antiinflammatory agents for inflammation; antiallergens for asthma | PHARMACIA CORPORATION (US) | 2006-02-14 | — | — | US | disclosed |
| US-20040147565-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. | 2004-07-29 | — | — | US | disclosed |
| US-6677364-B2 | ANTI-INFLAMMATORY, ANTIPYRETIC, ANALGESIC COMPOSITIONS | G.D. SEARLE & CO. | 2004-01-13 | — | — | US | disclosed |
| EP-0828736-B1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-0995747-B1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | SEARLE & CO (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020086886-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. | 2002-07-04 | — | — | US | disclosed |
| EP-0995747-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G.D. SEARLE & CO. (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0828736-A1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5643933-A | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | G. D. SEARLE & CO. (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996038442-A1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-12-05 | — | — | WO | disclosed |
| US-5281720-A | Antiasthmatics, antiallergens, antiinflammatory agents and cytoprotective agents | MERCK FROSST CANADA, INC. | 1994-01-25 | — | — | US | disclosed |
| US-5227399-A | Pyranylphenyl naphthalene lactones as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA, INC. (CA) | 1993-07-13 | — | — | US | disclosed |
| EP-0501579-A1 | Naphthalene lactones as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1992-09-02 | — | — | EP | disclosed |
| EP-0501578-A1 | Pyranylphenyl hydroxyalkylnaphthoic acids as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147565-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX12, ALOX15 | DRD3 4128/4885DRD2 3401/4885CYP19A1 461/4885 |
| US-20020086886-A1 | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, PTGES2, PTGS2 | DRD3 3714/4885DRD2 3053/4885CYP19A1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.